Nov 28, Biology/Cell & Microbiology This is the new picture of hepatitis C's E2 protein, which the virus uses to infect liver cells, will aid in the design of a vaccine against the disease.
Hepatitis C in the News Your source for hepatitis C-related news from around the web.
Not sure what to submit? Read our news guidelines first.
FDA NEWS RELEASE For Immediate Release: Nov. 22, 2013 Media Inquiries: Stephanie Yao, 301-796-0394, email@example.com Consumer Inquiries: 888-INFO-FDA FDA approves new treatment for hepatitis C virus The U.S. Food and Drug Administration today approved Olysio (simeprevir), a new therapy to treat chronic hepatitis C virus infection.
— Olysio may cut down on side effects while achieving good responses in patients, experts say.
ABT-450 Shows Promising Results for Hepatitis C Patients Print this page A Phase 2b trial of ABT-450 (a once-a-day, all-oral drug regimen) revealed an average sustained virologic response of 95 percent in newly-diagnosed patients.
Determined to get rid of the hepatitis C infection that was slowly destroying his liver, Arthur Rubens tried one experimental treatment after another. None worked, and most brought side effects, like fever, insomnia, depression, anemia and a rash that "felt like your skin was on fire."
The hepatitis C virus kills more people annually in the U.S. than HIV. Over the 24 years since the discoveryof the hepatitis C virus, many researchers have tried and failed to get a crystal structure of the two proteins used by the pathogen to infect its host and cause deadly…
— Drug blocks protein that helps virus replicate
Treating Hepatitis C Virus: How the Standard of Care is Evolving Hepatitis C virus (HCV), a major epidemic affecting an estimated 150 million people worldwide, is responsible for more than 350,000 annual deaths from HCV-related liver diseases.
— Interferon injections don't always work, but new therapies on the way, experts say.
— Review suggests it was associated with a 40 percent drop in risk of most common form of disease.